1147530-84-4

Basic information

• Product Name: 4-dimethylamino-N-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]benzamide
• Synonyms: 4-dimethylamino-N-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]benzamide
• CAS NO: 1147530-84-4
• Molecular Weight: 380.295
• Mol File: 1147530-84-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-dimethylamino-N-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-dimethylamino-N-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]benzamide(1147530-84-4)
• EPA Substance Registry System: 4-dimethylamino-N-[2-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]benzamide(1147530-84-4)

Safety Data

• Hazardous Substances Data: 1147530-84-4(Hazardous Substances Data)

Upstream product

• 4755-50-4 4-(dimethylamino)benzoyl chloride 
• 882678-96-8 2-methyl-3-( 4,4,5,5-tetramethyl[1,3,2]dioxaborolane-2-yl)phenylamine 
• 619-84-1 p-N,N-dimethylaminobenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 910235-64-2 2-(2-methyl-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 55289-35-5 2-bromo-6-nitrotoluene 

Relevant articles and documents

Pyrrolopyrimidine BTK inhibitor as well as preparation method and application thereof

The invention provides a pyrrolopyrimidine BTK inhibitor as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The compound has the structural general formula shown in a formula (I). In-flight

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.